LAURUSLABS Laurus Labs Q4 FY25 results (Jan–Mar 2025) and concall
Laurus Labs delivered a strong Q4 and FY25 performance, marked by significant revenue growth, margin expansion, and robust demand in its CDMO Small Molecule segment. The company is actively investing in new capacities for gene therapy, ADC, and fermentation, while also progressing its associate company ImmunoACT. Despite challenges in the large molecule CDMO and increased working capital, management remains confident in future growth and margin improvement, particularly from its diversified CDMO offerings.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 1,185 | 1,265 | 1,650 |
| EBITDA | 182 | 206 | 395 |
| Net profit | 42 | 57 | 252 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
